BR112017024115A2 - regulação de expressão genética mediada por nuclease - Google Patents
regulação de expressão genética mediada por nucleaseInfo
- Publication number
- BR112017024115A2 BR112017024115A2 BR112017024115A BR112017024115A BR112017024115A2 BR 112017024115 A2 BR112017024115 A2 BR 112017024115A2 BR 112017024115 A BR112017024115 A BR 112017024115A BR 112017024115 A BR112017024115 A BR 112017024115A BR 112017024115 A2 BR112017024115 A2 BR 112017024115A2
- Authority
- BR
- Brazil
- Prior art keywords
- nuclease
- gene expression
- mediated gene
- expression regulation
- genome
- Prior art date
Links
- 101710163270 Nuclease Proteins 0.000 title 1
- 230000014509 gene expression Effects 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 238000010362 genome editing Methods 0.000 abstract 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Materials For Medical Uses (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
a presente divulgação está no campo da engenharia do genoma, particularmente a modificação dirigida do genoma de uma célula hematopoiética.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562160396P | 2015-05-12 | 2015-05-12 | |
US201662303595P | 2016-03-04 | 2016-03-04 | |
PCT/US2016/032049 WO2016183298A2 (en) | 2015-05-12 | 2016-05-12 | Nuclease-mediated regulation of gene expression |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017024115A2 true BR112017024115A2 (pt) | 2018-08-07 |
Family
ID=57249092
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017024115A BR112017024115A2 (pt) | 2015-05-12 | 2016-05-12 | regulação de expressão genética mediada por nuclease |
Country Status (17)
Country | Link |
---|---|
US (2) | US10808020B2 (pt) |
EP (1) | EP3294866A4 (pt) |
JP (2) | JP6873917B2 (pt) |
KR (1) | KR20170141217A (pt) |
AU (2) | AU2016261927B2 (pt) |
BR (1) | BR112017024115A2 (pt) |
CA (1) | CA2984013A1 (pt) |
CL (1) | CL2017002843A1 (pt) |
CO (1) | CO2017012026A2 (pt) |
HK (1) | HK1251011A1 (pt) |
IL (3) | IL284707B2 (pt) |
MX (2) | MX2017014446A (pt) |
PH (1) | PH12017502026A1 (pt) |
SA (1) | SA517390307B1 (pt) |
SG (1) | SG10202112057QA (pt) |
WO (1) | WO2016183298A2 (pt) |
ZA (1) | ZA201707016B (pt) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012333134B2 (en) | 2011-07-22 | 2017-05-25 | John Paul Guilinger | Evaluation and improvement of nuclease cleavage specificity |
US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
US9340800B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | Extended DNA-sensing GRNAS |
PL3068881T3 (pl) * | 2013-11-13 | 2019-08-30 | Children's Medical Center Corporation | Regulacja ekspresji genów, w której pośredniczą nukleazy |
US9068179B1 (en) | 2013-12-12 | 2015-06-30 | President And Fellows Of Harvard College | Methods for correcting presenilin point mutations |
AU2015298571B2 (en) | 2014-07-30 | 2020-09-03 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
SG10202112057QA (en) * | 2015-05-12 | 2021-12-30 | Sangamo Therapeutics Inc | Nuclease-mediated regulation of gene expression |
CA2998500A1 (en) | 2015-09-23 | 2017-03-30 | Sangamo Therapeutics, Inc. | Htt repressors and uses thereof |
WO2017070632A2 (en) | 2015-10-23 | 2017-04-27 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
CA3032699A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
WO2018031683A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
EP3504327B1 (en) | 2016-08-24 | 2021-10-06 | Sangamo Therapeutics, Inc. | Engineered target specific nucleases |
JP7203014B2 (ja) | 2016-08-24 | 2023-01-12 | サンガモ セラピューティクス, インコーポレイテッド | 工学操作されたヌクレアーゼを使用した遺伝子発現の調節 |
EP3526320A1 (en) | 2016-10-14 | 2019-08-21 | President and Fellows of Harvard College | Aav delivery of nucleobase editors |
US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
TW201839136A (zh) | 2017-02-06 | 2018-11-01 | 瑞士商諾華公司 | 治療血色素異常症之組合物及方法 |
EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
JP2020510439A (ja) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
KR102687373B1 (ko) | 2017-03-23 | 2024-07-23 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제 |
WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
EP3658573A1 (en) | 2017-07-28 | 2020-06-03 | President and Fellows of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace) |
WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
CN111757937A (zh) | 2017-10-16 | 2020-10-09 | 布罗德研究所股份有限公司 | 腺苷碱基编辑器的用途 |
BR112020011255A2 (pt) * | 2017-12-05 | 2020-11-24 | Vertex Pharmaceuticals Incorporated | células-tronco e progenitoras hematopoiéticas cd34+ humanas modificadas por crispr-cas9 e usos das mesmas |
US11566236B2 (en) | 2018-02-05 | 2023-01-31 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of hemoglobinopathies |
US11690921B2 (en) | 2018-05-18 | 2023-07-04 | Sangamo Therapeutics, Inc. | Delivery of target specific nucleases |
CN112867792A (zh) | 2018-08-23 | 2021-05-28 | 桑格摩生物治疗股份有限公司 | 工程化靶特异性碱基编辑器 |
KR20210138569A (ko) | 2019-01-11 | 2021-11-19 | 아퀴타스 테라퓨틱스 인크. | 활성제의 지질 나노입자 전달을 위한 지질 |
WO2020191249A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
WO2020205838A1 (en) | 2019-04-02 | 2020-10-08 | Sangamo Therapeutics, Inc. | Methods for the treatment of beta-thalassemia |
MX2022014008A (es) | 2020-05-08 | 2023-02-09 | Broad Inst Inc | Métodos y composiciones para la edición simultánea de ambas cadenas de una secuencia de nucleótidos de doble cadena objetivo. |
AU2021308681A1 (en) | 2020-07-16 | 2023-03-09 | Acuitas Therapeutics, Inc. | Cationic lipids for use in lipid nanoparticles |
CA3200741A1 (en) * | 2020-12-01 | 2022-06-09 | Daniel Zurr | Methods for enhancing therapeutic efficacy of isolated cells for cell therapy |
EP4401757A1 (en) | 2021-09-13 | 2024-07-24 | Life Technologies Corporation | Gene editing tools |
EP4426832A1 (en) | 2021-11-03 | 2024-09-11 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Precise genome editing using retrons |
WO2023141602A2 (en) | 2022-01-21 | 2023-07-27 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
WO2024044723A1 (en) | 2022-08-25 | 2024-02-29 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
Family Cites Families (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2181548C (en) | 1994-01-18 | 2009-11-03 | Carlos F. Barbas, Iii | Zinc finger protein derivatives and methods therefor |
US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
US6242568B1 (en) | 1994-01-18 | 2001-06-05 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
USRE45721E1 (en) | 1994-08-20 | 2015-10-06 | Gendaq, Ltd. | Relating to binding proteins for recognition of DNA |
GB9824544D0 (en) | 1998-11-09 | 1999-01-06 | Medical Res Council | Screening system |
US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
GB9703369D0 (en) | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
GB2338237B (en) | 1997-02-18 | 2001-02-28 | Actinova Ltd | In vitro peptide or protein expression library |
GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
US6410248B1 (en) | 1998-01-30 | 2002-06-25 | Massachusetts Institute Of Technology | General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites |
EP1060261B1 (en) | 1998-03-02 | 2010-05-05 | Massachusetts Institute of Technology | Poly zinc finger proteins with improved linkers |
US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US7013219B2 (en) | 1999-01-12 | 2006-03-14 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
US7070934B2 (en) | 1999-01-12 | 2006-07-04 | Sangamo Biosciences, Inc. | Ligand-controlled regulation of endogenous gene expression |
US6599692B1 (en) | 1999-09-14 | 2003-07-29 | Sangamo Bioscience, Inc. | Functional genomics using zinc finger proteins |
US7030215B2 (en) | 1999-03-24 | 2006-04-18 | Sangamo Biosciences, Inc. | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
US6794136B1 (en) | 2000-11-20 | 2004-09-21 | Sangamo Biosciences, Inc. | Iterative optimization in the design of binding proteins |
AU776576B2 (en) | 1999-12-06 | 2004-09-16 | Sangamo Biosciences, Inc. | Methods of using randomized libraries of zinc finger proteins for the identification of gene function |
ATE483970T1 (de) | 2000-02-08 | 2010-10-15 | Sangamo Biosciences Inc | Zellen zur entdeckung von medikamenten |
US20020061512A1 (en) | 2000-02-18 | 2002-05-23 | Kim Jin-Soo | Zinc finger domains and methods of identifying same |
US20030044787A1 (en) | 2000-05-16 | 2003-03-06 | Joung J. Keith | Methods and compositions for interaction trap assays |
JP2002060786A (ja) | 2000-08-23 | 2002-02-26 | Kao Corp | 硬質表面用殺菌防汚剤 |
US7067317B2 (en) | 2000-12-07 | 2006-06-27 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
US20040224385A1 (en) | 2001-08-20 | 2004-11-11 | Barbas Carlos F | Zinc finger binding domains for cnn |
US7262054B2 (en) | 2002-01-22 | 2007-08-28 | Sangamo Biosciences, Inc. | Zinc finger proteins for DNA binding and gene regulation in plants |
CA2474486C (en) | 2002-01-23 | 2013-05-14 | The University Of Utah Research Foundation | Targeted chromosomal mutagenesis using zinc finger nucleases |
ATE531796T1 (de) | 2002-03-21 | 2011-11-15 | Sangamo Biosciences Inc | Verfahren und zusammensetzungen zur verwendung von zinkfinger-endonukleasen zur verbesserung der homologen rekombination |
US7074596B2 (en) | 2002-03-25 | 2006-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse mRNA cap analogues |
US7361635B2 (en) | 2002-08-29 | 2008-04-22 | Sangamo Biosciences, Inc. | Simultaneous modulation of multiple genes |
US9447434B2 (en) | 2002-09-05 | 2016-09-20 | California Institute Of Technology | Use of chimeric nucleases to stimulate gene targeting |
US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
US7253273B2 (en) | 2004-04-08 | 2007-08-07 | Sangamo Biosciences, Inc. | Treatment of neuropathic pain with zinc finger proteins |
CA2561714A1 (en) | 2004-04-08 | 2005-10-27 | Sangamo Biosciences, Inc. | Methods and compositions for treating neuropathic and neurodegenerative conditions |
CA2579677A1 (en) | 2004-09-16 | 2006-03-30 | Sangamo Biosciences, Inc. | Compositions and methods for protein production |
MX2007013757A (es) | 2005-05-05 | 2008-01-24 | Univ Arizona | Reagrupacion permitida de secuencia (seer)-met odo de novedad para visualizar secuencias de adn especificas. |
DE102005054628A1 (de) * | 2005-11-16 | 2007-05-24 | Cevec Pharmaceuticals Gmbh | Verfahren zur Herstellung von permanenten humanen Zelllinien |
JP5551432B2 (ja) | 2006-05-25 | 2014-07-16 | サンガモ バイオサイエンシーズ, インコーポレイテッド | 遺伝子不活性化のための方法と組成物 |
JP5266210B2 (ja) | 2006-05-25 | 2013-08-21 | サンガモ バイオサイエンシズ インコーポレイテッド | 改変開裂ハーフドメイン |
CA2684378C (en) | 2007-04-26 | 2016-11-29 | Sangamo Biosciences, Inc. | Targeted integration into the ppp1r12c locus |
PT2167523E (pt) | 2007-06-19 | 2014-09-22 | Univ Louisiana State | Síntese e utilização de análogos fosforotiolato antireversos do capuz de arn mensageiro |
KR101657504B1 (ko) | 2007-09-27 | 2016-09-19 | 상가모 바이오사이언스 인코포레이티드 | 생물학적으로 활성인 뉴클레아제의 신속한 생체내 확인 |
AU2009238629C1 (en) | 2008-04-14 | 2015-04-30 | Sangamo Therapeutics, Inc. | Linear donor constructs for targeted integration |
CA2725773C (en) | 2008-05-28 | 2017-12-05 | Sangamo Biosciences, Inc. | Compositions for linking dna-binding domains and cleavage domains |
JP5908725B2 (ja) | 2008-08-22 | 2016-04-26 | サンガモ バイオサイエンシーズ, インコーポレイテッド | 標的一本鎖開裂および標的組込みのための方法、並びに組成物 |
CA2737180C (en) | 2008-09-15 | 2019-02-19 | Children's Medical Center Corporation | Modulation of bcl11a for treatment of hemoglobinopathies |
CA2745031C (en) | 2008-12-04 | 2018-08-14 | Sangamo Biosciences, Inc. | Genome editing in rats using zinc-finger nucleases |
WO2011016840A2 (en) * | 2009-07-28 | 2011-02-10 | Sangamo Biosciences, Inc. | Methods and compositions for treating trinucleotide repeat disorders |
EP3581197A1 (de) | 2009-07-31 | 2019-12-18 | ethris GmbH | Rna mit einer kombination aus unmodifizierten und modifizierten nucleotiden zur proteinexpression |
US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
JP6137596B2 (ja) | 2010-02-08 | 2017-05-31 | サンガモ セラピューティクス, インコーポレイテッド | 遺伝子操作された切断ハーフドメイン |
CA2788850C (en) | 2010-02-09 | 2019-06-25 | Sangamo Biosciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
CA2796600C (en) | 2010-04-26 | 2019-08-13 | Sangamo Biosciences, Inc. | Genome editing of a rosa locus using zinc-finger nucleases |
US8772453B2 (en) | 2010-05-03 | 2014-07-08 | Sangamo Biosciences, Inc. | Compositions for linking zinc finger modules |
JP6208580B2 (ja) | 2010-05-17 | 2017-10-04 | サンガモ セラピューティクス, インコーポレイテッド | 新規のdna結合タンパク質及びその使用 |
CA2805442C (en) | 2010-07-21 | 2020-05-12 | Sangamo Biosciences, Inc. | Methods and compositions for modification of an hla locus |
WO2012094132A1 (en) | 2011-01-05 | 2012-07-12 | Sangamo Biosciences, Inc. | Methods and compositions for gene correction |
US9150847B2 (en) | 2011-09-21 | 2015-10-06 | Sangamo Biosciences, Inc. | Methods and compositions for regulation of transgene expression |
CA3099582A1 (en) | 2011-10-27 | 2013-05-02 | Sangamo Biosciences, Inc. | Methods and compositions for modification of the hprt locus |
AU2012340213B2 (en) | 2011-11-16 | 2017-12-07 | Sangamo Therapeutics, Inc. | Modified DNA-binding proteins and uses thereof |
DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
CN104471067B (zh) | 2012-05-07 | 2020-08-14 | 桑格摩生物治疗股份有限公司 | 用于核酸酶介导的转基因靶向整合的方法和组合物 |
AR092839A1 (es) * | 2012-05-28 | 2015-05-06 | Evogene Ltd | Polinucleotidos y polipeptidos aislados y metodos para utilizarlos para mejorar el rendimiento y/o caracteristicas agricolas de las plantas |
SG10201701601WA (en) | 2012-08-29 | 2017-04-27 | Sangamo Biosciences Inc | Methods and compositions for treatment of a genetic condition |
CN109554350B (zh) * | 2012-11-27 | 2022-09-23 | 儿童医疗中心有限公司 | 用于胎儿血红蛋白再诱导的靶向bcl11a远端调控元件 |
WO2014089212A1 (en) | 2012-12-05 | 2014-06-12 | Sangamo Biosciences, Inc. | Methods and compositions for regulation of metabolic disorders |
CN105683376A (zh) | 2013-05-15 | 2016-06-15 | 桑格摩生物科学股份有限公司 | 用于治疗遗传病状的方法和组合物 |
EP3039136B8 (en) | 2013-08-28 | 2020-12-16 | Sangamo Therapeutics, Inc. | Compositions for linking dna-binding domains and cleavage domains |
PL3068881T3 (pl) | 2013-11-13 | 2019-08-30 | Children's Medical Center Corporation | Regulacja ekspresji genów, w której pośredniczą nukleazy |
AU2015255877B2 (en) | 2014-05-08 | 2020-03-26 | Chdi Foundation, Inc. | Methods and compositions for treating huntington's disease |
EP3294873B2 (en) | 2015-05-08 | 2024-09-18 | The Children's Medical Center Corporation | Targeting bcl11a enhancer functional regions for fetal hemoglobin reinduction |
SG10202112057QA (en) * | 2015-05-12 | 2021-12-30 | Sangamo Therapeutics Inc | Nuclease-mediated regulation of gene expression |
EA201891532A1 (ru) * | 2015-12-28 | 2019-01-31 | Новартис Аг | Композиции и способы лечения гемоглобинопатий |
SG11201809144XA (en) * | 2016-04-18 | 2018-11-29 | Crispr Therapeutics Ag | Materials and methods for treatment of hemoglobinopathies |
-
2016
- 2016-05-12 SG SG10202112057QA patent/SG10202112057QA/en unknown
- 2016-05-12 AU AU2016261927A patent/AU2016261927B2/en active Active
- 2016-05-12 MX MX2017014446A patent/MX2017014446A/es unknown
- 2016-05-12 CA CA2984013A patent/CA2984013A1/en active Pending
- 2016-05-12 IL IL284707A patent/IL284707B2/en unknown
- 2016-05-12 BR BR112017024115A patent/BR112017024115A2/pt active Search and Examination
- 2016-05-12 KR KR1020177032403A patent/KR20170141217A/ko not_active Application Discontinuation
- 2016-05-12 WO PCT/US2016/032049 patent/WO2016183298A2/en active Application Filing
- 2016-05-12 EP EP16793510.5A patent/EP3294866A4/en active Pending
- 2016-05-12 JP JP2017559044A patent/JP6873917B2/ja active Active
- 2016-05-12 US US15/565,811 patent/US10808020B2/en active Active
-
2017
- 2017-10-17 ZA ZA2017/07016A patent/ZA201707016B/en unknown
- 2017-10-26 IL IL255288A patent/IL255288B/en unknown
- 2017-11-07 PH PH12017502026A patent/PH12017502026A1/en unknown
- 2017-11-08 SA SA517390307A patent/SA517390307B1/ar unknown
- 2017-11-09 CL CL2017002843A patent/CL2017002843A1/es unknown
- 2017-11-10 MX MX2021005226A patent/MX2021005226A/es unknown
- 2017-11-27 CO CONC2017/0012026A patent/CO2017012026A2/es unknown
-
2018
- 2018-08-13 HK HK18110341.5A patent/HK1251011A1/zh unknown
-
2020
- 2020-09-15 US US17/021,555 patent/US20210024606A1/en not_active Abandoned
-
2021
- 2021-04-21 JP JP2021071881A patent/JP7365374B2/ja active Active
- 2021-10-06 IL IL287033A patent/IL287033A/en unknown
-
2022
- 2022-07-06 AU AU2022204863A patent/AU2022204863A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2017014446A (es) | 2018-06-13 |
CO2017012026A2 (es) | 2018-02-28 |
IL255288B (en) | 2021-10-31 |
CA2984013A1 (en) | 2016-11-17 |
JP2018516556A (ja) | 2018-06-28 |
AU2016261927B2 (en) | 2022-04-07 |
JP2021106611A (ja) | 2021-07-29 |
WO2016183298A2 (en) | 2016-11-17 |
AU2016261927A1 (en) | 2017-11-02 |
IL284707A (en) | 2021-08-31 |
EP3294866A4 (en) | 2018-12-05 |
ZA201707016B (en) | 2019-08-28 |
CL2017002843A1 (es) | 2018-05-25 |
KR20170141217A (ko) | 2017-12-22 |
AU2022204863A1 (en) | 2022-07-28 |
US20180111975A1 (en) | 2018-04-26 |
MX2021005226A (es) | 2021-06-18 |
PH12017502026A1 (en) | 2018-04-02 |
IL284707B2 (en) | 2024-01-01 |
SA517390307B1 (ar) | 2021-07-13 |
US20210024606A1 (en) | 2021-01-28 |
IL255288A0 (en) | 2017-12-31 |
JP7365374B2 (ja) | 2023-10-19 |
IL287033A (en) | 2021-12-01 |
WO2016183298A3 (en) | 2016-12-29 |
US10808020B2 (en) | 2020-10-20 |
SG10202112057QA (en) | 2021-12-30 |
HK1251011A1 (zh) | 2019-01-18 |
IL284707B1 (en) | 2023-09-01 |
EP3294866A2 (en) | 2018-03-21 |
JP6873917B2 (ja) | 2021-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017024115A2 (pt) | regulação de expressão genética mediada por nuclease | |
BR112019003100A2 (pt) | regulação da expressão gênica usando nucleases manipuladas | |
CY1121630T1 (el) | Ρυθμιση της εκφρασης γονιδιου σφαιρινης διαμεσολαβουμενη απο νουκλεασες | |
DK3684930T3 (da) | Modificering af ikke-kodende plante-RNA-molekylers specificitet for inaktivering af genekspression | |
HK1258739A1 (zh) | 多能細胞的基因組工程改造 | |
HK1248760A1 (zh) | 通過對選擇性剪接進行適體介導的調節來實現的基因表達調控 | |
GB2544001A (en) | Methods for increasing Cas9-mediated engineering efficiency | |
MX2017010638A (es) | Derivados de sobetiroma. | |
PH12015502401A1 (en) | Compositions and methods for enhancing microbial stability | |
DOP2022000085A (es) | Composiciones y métodos para inhibir la expresión del gen alas1 | |
MX2017016623A (es) | Variantes de quimosina con propiedades mejoradas. | |
DK3268484T3 (da) | Enzymatisk flertrinshydrolyse af lignocelluloseholdig biomasse | |
BR112017000211A2 (pt) | composição de revestimento estável | |
BR112017024855A2 (pt) | métodos de produção de aldc | |
EP3493826A4 (en) | MULTIVITAMINS CAPABLE OF REGULATING BENEFICIAL GENES VIA MICRO-RNA (MIARN) | |
GB201511482D0 (en) | Culture of RPE cells | |
EA201990568A1 (ru) | Регулирование экспрессии генов с использованием сконструированных нуклеаз | |
ZA202310780B (en) | Compositions and methods for enhanced gene expression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] |